alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015089EN.01000401.xml

| 16.3.2015 | EN | Official Journal of the European Union | C 89/4 |
| --- | --- | --- | --- |

16.3.2015

EN

Official Journal of the European Union

C 89/4

---

Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 17 December 2014 — Patrick Breyer v Bundesrepublik Deutschland

(Case C-582/14)

(2015/C 089/05)

Language of the case: German

Referring court

Referring court

Bundesgerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Patrick Breyer

Applicant:

Defendant: Bundesrepublik Deutschland

Defendant:

Questions referred

Questions referred

| 1. | Must Article 2(a) of Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (1) — the Data Protection Directive — be interpreted as meaning that an Internet Protocol address (IP address) which a service provider stores when his website is accessed already constitutes personal data for the service provider if a third party (an access provider) has the additional knowledge required in order to identify the data subject? |
| --- | --- |

1.

Must Article 2(a) of Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data (1) — the Data Protection Directive — be interpreted as meaning that an Internet Protocol address (IP address) which a service provider stores when his website is accessed already constitutes personal data for the service provider if a third party (an access provider) has the additional knowledge required in order to identify the data subject?

1

| 2. | Does Article 7(f) of the Data Protection Directive preclude a provision in national law under which a service provider may collect and use a user’s personal data without his consent only to the extent necessary in order to facilitate, and charge for, the specific use of the telemedium by the user concerned, and under which the purpose of ensuring the general operability of the telemedium cannot justify use of the data beyond the end of the particular use of the telemedium? |
| --- | --- |

2.

Does Article 7(f) of the Data Protection Directive preclude a provision in national law under which a service provider may collect and use a user’s personal data without his consent only to the extent necessary in order to facilitate, and charge for, the specific use of the telemedium by the user concerned, and under which the purpose of ensuring the general operability of the telemedium cannot justify use of the data beyond the end of the particular use of the telemedium?

---

(1)  OJ 1995 L 281, p. 31.

1

---
§ 573.587 Komagataella pastoris dried yeast. ( a ) *Identity.* The food additive *Komagataella pastoris* dried yeast is non-viable and may be used in feed formulations of broiler chickens as a source of protein not to exceed 10 percent by weight of the total formulation.
( b ) *Specifications.* The additive shall conform to the following percent-by-weight specifications: ( 1 ) Crude protein, not less than 60 percent.
( 2 ) Crude fat, not less than 2 percent.
( 3 ) Crude fiber, not more than 2 percent.
( 4 ) Ash, not more than 13 percent.
( 5 ) Moisture, not more than 6 percent.
( c ) *Use.* To ensure safe use, the labeling of the additive and any feed additive supplement, concentrate, or premix prepared therefrom shall bear, in addition to other required information, the name of the additive, directions for use to provide not more than 10 percent by weight of the total ration, and the statement “Caution: Not to be used in layers or other poultry intended for breeding.”
[58 FR 59170, Nov. 8, 1993. Redesignated and amended at 89 FR 72315, Sept. 5, 2024]
I 

118TH CONGRESS 

2D SESSION H. R. 7601 

To amend the Defense Production Act of 1950 to prohibit the use of the 

authorities under title I and title III of such Act for electric vehicles 

or related technologies. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 8, 2024 

Mr. PERRY introduced the following bill; which was referred to the Committee 

on Financial Services 

A BILL 

To amend the Defense Production Act of 1950 to prohibit 

the use of the authorities under title I and title III 

of such Act for electric vehicles or related technologies. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Bullets Not Batteries 

5 Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7601 IH

1 SEC. 2. PROHIBITION ON THE USE OF AUTHORITIES FOR 

2 ELECTRIC VEHICLES AND RELATED TECH3 NOLOGY. 

4 Section 104 of the Defense Production Act of 1950 

5 (50 U.S.C. 4514) is amended by adding at the end the 

6 following: 

7 ‘‘(c) ELECTRIC VEHICLES AND RELATED TECH8 NOLOGY.—The authorities provided under this title and 

9 title III may not be used with respect to— 

10 ‘‘(1) electric vehicles; 

11 ‘‘(2) electric vehicle batteries; 

12 ‘‘(3) electric vehicle charging stations or other 

13 electric vehicle infrastructure; or 

14 ‘‘(4) obtaining critical minerals that will be 

15 used for the manufacturing of any item described 

16 under paragraph (1), (2), or (3).’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 522.1079 Serum gonadotropin and chorionic gonadotropin. ( a ) *Specifications.* Each dose consists of 400 international units (I.U.) serum gonadotropin and 200 I.U. chorionic gonadotropin as a freeze-dried powder to be reconstituted with 5 milliliters of sterile aqueous diluent.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.304 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amount.* 400 I.U. serum gonadotropin with 200 I.U. chorionic gonadotropin per 5 milliliters dose per animal.
( 2 ) *Indications for use* — ( i ) *Gilts.* For induction of fertile estrus (heat) in healthy prepuberal (noncycling) gilts.
( ii ) *Sows.* For induction of estrus in healthy weaned sows experiencing delayed return to estrus.
( 3 ) *Limitations.* For subcutaneous use only. ( i ) *Gilts.* For use only in gilts over 51 ⁄ 2 months of age and weighing at least 85 kilograms (187 pounds).
( ii ) *Sows.* Delayed return to estrus is most prevalent after the first litter. The effectiveness has not been established after later litters. Delayed return to estrus often occurs during periods of adverse environmental conditions, and sows mated under such conditions may farrow smaller than normal litters.
[55 FR 1405, Jan. 16, 1990, as amended at 58 FR 52222, Oct. 7, 1993; 74 FR 61516, Nov. 25, 2009; 84 FR 32992, July 11, 2019]
§ 640.82 Tests on final product. Tests shall be performed on the final product to determine that it meets the following standards: ( a ) *Protein concentration.* Final product shall conform to one of the following concentrations: 4.0 ±0.25 percent; 5.0 ±0.30 percent; 20.0 ±1.2 percent; and 25.0 ±1.5 percent solution of protein.
( b ) *Protein composition.* At least 96 percent of the total protein in the final product shall be albumin, as determined by a method that has been approved for each manufacturer by the Director, Center for Biologics Evaluation and Research, Food and Drug Administration.
( c ) *pH.* The pH shall be 6.9 ±0.5 when measured in a solution of the final product diluted to a concentration of 1 percent protein with 0.15 molar sodium chloride.
( d ) *Sodium concentration.* The sodium concentration of the final product shall be 130 to 160 milliequivalents per liter.
( e ) *Potassium concentration.* The potassium concentration of the final product shall not exceed 2 milliequivalents per liter.
( f ) *Heat stability.* A final container sample of Albumin (Human) shall remain unchanged, as determined by visual inspection, after heating at 57 °C for 50 hours, when compared to its control consisting of a sample, from the same lot, which has not undergone this heating.
[42 FR 27582, May 31, 1977, as amended at 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 64 FR 26286, May 14, 1999]
Exhibit 4.1


 


THE BANK OF NEW YORK MELLON


NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON


 


 


2 HANSON PLACE, 12TH FLOOR, BROOKLYN,
N.Y. 11217


 


 


 


April 26, 2017


 


Hennion & Walsh, Inc.


2001 Route 46, Waterview Plaza


Parsippany, New Jersey 07054


 


Smart Trust 314


 


Dear Sirs:


The Bank of New York
Mellon is acting as trustee for the series of Smart Trust set forth above (the “Trust”). We enclosed a list
of the Securities to be deposited in the Trust on the date hereof. The prices indicated therein reflect our evaluation of such
Securities as of close of business on April 25, 2017, in accordance with the valuation method set forth in the Standard Terms and
Conditions of Trust and Trust Agreement. We consent to the reference to The Bank of New York Mellon as the party performing the
evaluations of the Trust Securities in the Registration Statement (No. 333-215957) filed with the Securities and Exchange Commission
with respect to the registration of the sale of the Trust Units and to the filing of this consent as an exhibit thereto.


 


 


Very truly yours,


 


/s/ GERARDO CIPRIANO                      


Gerardo Cipriano


Vice President
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AND STATEMENT OF OPERATIONS INCLUDED IN THE COMPANY'S FORM 10-K FOR THE
YEAR ENDED DECEMBER 31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          43,251
<SECURITIES>                                     6,519
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                53,901
<PP&E>                                           6,283
<DEPRECIATION>                                   3,679
<TOTAL-ASSETS>                                  57,139
<CURRENT-LIABILITIES>                           11,132
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            19
<OTHER-SE>                                      27,994
<TOTAL-LIABILITY-AND-EQUITY>                    57,139
<SALES>                                         10,494
<TOTAL-REVENUES>                                10,494
<CGS>                                            9,945
<TOTAL-COSTS>                                    9,945
<OTHER-EXPENSES>                                28,335
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (27,344)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (27,344)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (27,344)
<EPS-BASIC>                                     (1.88)
<EPS-DILUTED>                                   (1.88)


</TABLE>
§ 520.2002 Propiopromazine. ( a ) *Specifications.* Each chewable tablet contains 10 or 20 milligrams of propiopromazine hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 0.5 to 2.0 milligrams per pound of body weight once or twice daily, depending upon the degree of tranquilization desired.
( 2 ) *Indications for use.* For oral administration as a tranquilizer. As an aid in handling difficult, excited, and unruly dogs, and in controlling excessive kennel barking, car sickness, and severe dermatitis. It is also indicated for use in minor surgery and prior to routine examinations, laboratory procedures, and diagnostic procedures.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28827, May 20, 2014]
###### Editorial Note on Part 570

#### Editorial Note:

Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

#### § 570.245 Part 5 of a GRAS notice: Experience based on common use in food before 1958.

If the statutory basis for your conclusion of GRAS status is through experience based on common use in animal food, in Part 5 of your GRAS notice you must include evidence of a substantial history of consumption of the notified substance for food use by a significant number of animals of the species to which the substance is intended to be fed prior to January 1, 1958, and evidence of a substantial history of consumption by humans consuming human foods derived from food-producing animals prior to January 1, 1958.
§ 640.56 Quality control test for potency. ( a ) Quality control tests for potency of antihemophilic factor shall be conducted each month on at least four representative containers of Cryoprecipitated AHF.
( b ) The results of each test are received by the establishment licensed for Cryoprecipitated AHF within 30 days of the preparation of the cryoprecipitated antihemophilic factor and are maintained at that establishment so that they may be reviewed by an authorized representative of the Food and Drug Administration.
( c ) The quality control test for potency may be performed by a clinical laboratory which meets the standards of the Clinical Laboratories Improvement Amendments of 1988 (CLIA) (42 U.S.C. 263a) and is qualified to perform potency tests for antihemophilic factor. Such arrangements must be approved by the Director, Center for Biologics Evaluation and Research, Food and Drug Administration. Such testing shall not be considered as divided manufacturing, as described in § 610.63 of this chapter, provided the following conditions are met: ( 1 ) The establishment licensed for Cryoprecipitated AHF has obtained a written agreement that the testing laboratory will permit an authorized representative of the Food and Drug Administration to inspect its testing procedures and facilities during reasonable business hours.
( 2 ) The testing laboratory will participate in any proficiency testing programs undertaken by the Center for Biologics Evaluation and Research, Food and Drug Administration.
( d ) If the average potency level of antihemophilic factor in the containers tested is less than 80 units of antihemophilic factor per container, immediate corrective actions shall be taken and a record maintained of such action.
[42 FR 21774, Apr. 29, 1977, as amended at 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 64 FR 45373, Aug. 19, 1999; 66 FR 1837, Jan. 10, 2001]
# EUR-Lex - 31993D0722 - EN

Avis juridique important

*|*

# 31993D0722

**93/722/EC: Council Decision of 23 November 1993 concerning the conclusion of an Agreement between the European Community and Republic of Bulgaria on the reciprocal protection and control of wine names **

*
Official Journal L 337 , 31/12/1993 P. 0011 - 0011 Finnish special edition: Chapter 3 Volume 54 P. 0214 Swedish special edition: Chapter 3 Volume 54 P. 0214 *

COUNCIL DECISION of 23 November 1993 concerning the conclusion of an Agreement between the European Community and Republic of Bulgaria on the reciprocal protection and control of wine names (93/722/EC)

THE COUNCIL OF THE EUROPEAN UNION Having regard to the Treaty establishing the European Community, and in particular Article 113 thereof,

Having regard to the proposal from the Commission,

Whereas the Agreement negotiated between the European Community and the Republic of Bulgaria on the reciprocal protection and control of wine names will help make measures to eliminate unfair competition in trade more effective, ensure a greater degree of consumer protection and promote trade in wine between the Contracting Parties; whereas it is therefore desirable to approve the said Agreement;

Whereas, in order to facilitate the implementation of certain provisions of the Agreement, the Commission should be authorized to make the necessary technical adjustments in accordance with the procedure laid down in Article 83 of Council Regulation (EEC) No 822/87 of 16 March 1987 on the common organization of the market in wine (1);

Whereas, since the provisions of the Agreement are directly linked to measures covered by the common commercial and agricultural policy, the said Agreement must be established at Community level,

HAS DECIDED AS FOLLOWS:

Article 1

The Agreement between the European Community and the Republic of Bulgaria on the reciprocal protection and control of wine names and the Protocol annexed thereto are hereby approved on behalf of the Community.

The text of the acts referred to in the first paragraph are attached to this Decision.

Article 2

The President of the Council is hereby authorized to designate the person empowered to sign the Agreement and to deposit the instrument of approval by the Community.

The President of the Council shall make the notification provided for in Article 19 (1) of the Agreement.

Article 3

For the purposes of Article 13 of the Agreement, the Commission is hereby authorized to conclude the necessary acts amending the Agreement, in accordance with the procedure laid down in Article 83 of Regulation (EEC) No 822/87.

Article 4

This Decision shall be published in the Official Journal of the European Communities.

Done at Brussels, 23 November 1993.

For the Council The President M. SMET

(1) OJ No L 84, 27. 3. 1987, p. 1. Regulation as last amended by Regulation (EEC) No 1566/93 (OJ No L 154, 25. 6. 1993, p. 39.
EXHIBIT 32.2
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB/A  for the period ending March 31, 2006 as filed with the  Securities
and Exchange Commission on the date hereof (the "Report"), I, Jay C. Leatherman,
Jr.,  Chief  Financial  Officer of the  Company  certify,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, to my knowledge, that:

(1)  The Report fully complies with the requirements of Section 13(a) or15(d) of
     the Securities Exchange Act of 1934; and

(2)  The information  contained in the Report fairly  presents,  in all material
     respects, the financial condition and results of operations of the Company.

Date: May 15, 2006

                                  /s/ Jay C. Leatherman, Jr.
                                  -------------------------
                                  Jay C. Leatherman, Jr.
                                  Chief Financial Officer (Principal Financial
                                  and Accounting Officer), Secretary
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.3 Definitions. As used in this part: ( a ) *Bronchodilator drug.* A drug used to overcome spasms that cause narrowing of the bronchial air tubes, such as in the symptomatic treatment of the wheezing and shortness of breath of asthma.
( b ) *Oral antitussive drug.* A drug that either is taken by mouth or is dissolved in the mouth in the form of a lozenge and acts systemically to relieve cough.
( c ) *Topical antitussive drug.* A drug that relieves cough when inhaled after being applied topically to the throat or chest in the form of an ointment or from a steam vaporizer, or when dissolved in the mouth in the form of a lozenge for a local effect.
( d ) *Expectorant drug.* A drug taken orally to promote or facilitate the removal of secretions from the respiratory airways.
( e ) *Antihistamine drug.* A drug used for the relief of the symptoms of hay fever and upper respiratory allergies (allergic rhinitis).
( f ) *Oral nasal decongestant drug.* A drug that is taken by mouth and acts systemically to reduce nasal congestion caused by acute or chronic rhinitis.
( g ) *Topical nasal decongestant drug.* A drug that when applied topically inside the nose, in the form of drops, jellies, or sprays, or when inhaled intranasally reduces nasal congestion caused by acute or chronic rhinitis.
( h ) *Calibrated dropper.* A dropper calibrated such that the volume error incurred in measuring any liquid does not exceed 15 percent under normal use conditions.
( i ) *Effervescent dosage form.* A dosage form intended to be dissolved in water before administration. It contains, in addition to the active ingredient(s), mixtures of acids (citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water.
[51 FR 35339, Oct. 2, 1986, as amended at 54 FR 8509, Feb. 28, 1989; 55 FR 40382, Oct. 3, 1990; 57 FR 58374, Dec. 9, 1992; 59 FR 43409, Aug. 23, 1994; 71 FR 43362, Aug. 1, 2006]
[Federal Register Volume 75, Number 35 (Tuesday, February 23, 2010)]
[Notices]
[Page 8156]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3643]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


Electronic Game Card, Inc.; Order of Suspension of Trading

February 19, 2010.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Electronic Game Card, Inc. (``EGMI'') because of questions regarding 
the accuracy of assertions by EGMI, and by others, in financial 
disclosures to investors concerning, among other things, the company's 
assets.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed company.
    Therefore, it is ordered, pursuant to Section 12(k) of the 
Securities Exchange Act of 1934, that trading in the securities of the 
above-listed company is suspended for the period from 9:30 a.m. EST, on 
February 19, 2010, through 11:59 p.m. EST, on March 4, 2010.

    By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2010-3643 Filed 2-19-10; 4:15 pm]
BILLING CODE 8011-01-P
Exhibit 32.1
 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934
  (1)
    
    the Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934, as amended; and
 (2)
    
    the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 August 13, 2009
    
    By:
    
    /s/ David GoldbergDavid GoldbergPresident and Chief Executive OfficerAugust 13, 2009
    
    By:
    
    /s/ Michael NelsonMichael NelsonChief Accounting Officer